{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:36:08Z","timestamp":1787506568641,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006701","name":"Umm Al-Qura University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.bioorg.2024.107284","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T03:54:09Z","timestamp":1710302049000},"page":"107284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Discovery of novel benzimidazole derivatives as potent HDACs inhibitors against leukemia with (Thio)Hydantoin as zinc-binding moiety: Design, synthesis, enzyme inhibition, and cellular mechanistic study"],"prefix":"10.1016","volume":"146","author":[{"given":"Hanan Gaber","family":"Abdulwahab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda El-Sayed","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thoraya A","family":"Farghaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hend M.","family":"El-Sehrawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bioorg.2024.107284_b0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00439-013-1271-x","article-title":"Genetic syndromes caused by mutations in epigenetic genes","volume":"132","author":"Berdasco","year":"2013","journal-title":"Hum. Genet."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107284_b0010","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome - biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2024.107284_b0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4137\/GEG.S12270","article-title":"Use of epigenetic drugs in disease: an overview","volume":"6","author":"Heerboth","year":"2014","journal-title":"Genet. Epigenet."},{"issue":"7766","key":"10.1016\/j.bioorg.2024.107284_b0020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41586-019-1411-0","article-title":"Advances in epigenetics link genetics to the environment and disease","volume":"571","author":"Cavalli","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bioorg.2024.107284_b0025","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107284_b0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bioorg.2024.107284_b0035","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.tcb.2013.06.001","article-title":"Transcriptional control of cancer metastasis","volume":"23","author":"Ell","year":"2013","journal-title":"Trends Cell Biol."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107284_b0040","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/cas.13062","article-title":"Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies","volume":"107","author":"Imai","year":"2016","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107284_b0045","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0654-9","article-title":"Histone deacetylase 6 in cancer","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107284_b0050","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107284_b0055","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bioorg.2024.107284_b0060","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","article-title":"Inside HDACs with more selective HDAC inhibitors","volume":"121","author":"Roche","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107284_b0065","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3390\/ijms19082337","article-title":"The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease","volume":"19","author":"Cosenza","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107284_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105274","article-title":"HDAC6 as privileged target in drug discovery: a perspective","volume":"163","author":"Pulya","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"24","key":"10.1016\/j.bioorg.2024.107284_b0075","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2174\/092986705774454706","article-title":"Non-hydroxamate histone deacetylase inhibitors","volume":"12","author":"Suzuki","year":"2005","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107284_b0080","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13065-019-0579-6","article-title":"Benzimidazole scaffolds as promising antiproliferative agents: a review","volume":"13","author":"Tahlan","year":"2019","journal-title":"BMC Chemistry"},{"issue":"6","key":"10.1016\/j.bioorg.2024.107284_b0085","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201700040","article-title":"Benzimidazole scaffold as anticancer agent: synthetic approaches and structure-activity relationship","volume":"350","author":"Shrivastava","year":"2017","journal-title":"Arch. Pharm."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107284_b0090","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bmc.2013.12.029","article-title":"Synthesis and evaluation of novel benzimidazole derivatives as sirtuin inhibitors with antitumor activities","volume":"22","author":"Yoon","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107284_b0095","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.bmcl.2009.01.041","article-title":"N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity","volume":"19","author":"Wang","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"17","key":"10.1016\/j.bioorg.2024.107284_b0100","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1016\/j.bmcl.2013.07.001","article-title":"Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents","volume":"23","author":"Wang","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107284_b0105","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejmech.2018.12.066","article-title":"Recent applications of hydantoin and thiohydantoin in medicinal chemistry","volume":"164","author":"Cho","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2024.107284_b0110","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1016\/j.bmcl.2013.05.089","article-title":"Hydantoin based inhibitors of MMP13\u2013discovery of AZD6605","volume":"23","author":"De Savi","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107284_b0115","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1039\/C4MD00171K","article-title":"Benzylidene-linked thiohydantoin derivatives as inhibitors of tyrosinase and melanogenesis: importance of the \u03b2-phenyl-\u03b1, \u03b2-unsaturated carbonyl functionality","volume":"5","author":"Kim","year":"2014","journal-title":"Med. Chem. Commun."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107284_b0120","doi-asserted-by":"crossref","first-page":"e2200433","DOI":"10.1002\/ardp.202200433","article-title":"Novel benzimidazole-linked (thio)barbiturates as non-hydroxamate HDAC6 inhibitors targeting leukemia: design, synthesis, and structure-activity relationship","volume":"356","author":"Mansour","year":"2023","journal-title":"Arch. Pharm."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107284_b0125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.21608\/aijpms.2021.78337.1077","article-title":"Novel Mannich bases derived from 2-substituted benzimidazole and (thio)hydantoin moieties as potent histone deacetylase 6 (HDAC6) inhibitors","volume":"1","author":"Mansour","year":"2021","journal-title":"Azhar Int. J. Pharm. Med. Sci."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107284_b0130","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2024.107284_b0135","doi-asserted-by":"crossref","unstructured":"Sami A. Al-Hussain, Thoraya A. Farghaly, Magdi E.A. Zaki, Hanan G. Abdulwahab, Nadia T. Al-Qurashi, Zeinab A. Muhammad Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity Bioorganic Chemistry 105 (2020) 104330. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104330.","DOI":"10.1016\/j.bioorg.2020.104330"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107284_b0140","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1080\/14756366.2022.2112575","article-title":"Discovery of new 1H-pyrazolo[3,4-d]pyrimidine derivatives as anticancer agents targeting EGFRWT and EGFRT790M","volume":"37","author":"Gaber","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107284_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2017.03.038","article-title":"Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents","volume":"134","author":"Xie","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107284_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106043","article-title":"Novel 6, 7, 8-trihydrobenzo [6', 7'] cyclohepta [2', 1'-e] pyrazolo [2, 3-a] pyrimidine derivatives as Topo II\u03b1 inhibitors with potential cytotoxic activity","volume":"128","author":"Farghaly","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107284_b0155","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1158\/1535-7163.MCT-06-0209","article-title":"Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells","volume":"5","author":"Dowdy","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2024.107284_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112411","article-title":"PTG-0861: a novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia","volume":"201","author":"Gawel","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107284_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105058","article-title":"The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia","volume":"160","author":"Losson","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2024.107284_b0170","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejmech.2018.12.056","article-title":"A novel class of anthraquinone-based HDAC6 inhibitors","volume":"164","author":"Song","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107284_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111725","article-title":"N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-\u03b3 induced PD-L1 expression","volume":"185","author":"Mehndiratta","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107284_b0180","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107284_b0185","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107284_b0190","first-page":"678","article-title":"Studies on acetamide derivatives. Part-II. preparation, antimicrobial and anthelmintic activity of N-arylaminoacetylbenzimidazole\/sulphadiazine or sulphamethazine and N-arylbenzimidazol-l-yl\/sulphadiazin-4-yl or sulphamethazin-4-yl\/acetamides","volume":"64","author":"Shah","year":"1987","journal-title":"J. Indian Chem. Soc."},{"issue":"42","key":"10.1016\/j.bioorg.2024.107284_b0195","doi-asserted-by":"crossref","first-page":"27355","DOI":"10.1039\/D2RA03624J","article-title":"Novel thiazole derivatives incorporating phenyl sulphonyl moiety as potent BRAFV600E kinase inhibitors targeting melanoma","volume":"12","author":"Khormi","year":"2022","journal-title":"RSC Adv."},{"issue":"208","key":"10.1016\/j.bioorg.2024.107284_b0200","article-title":"Novel 2-indolinone thiazole hybrids as sunitinib analogues: design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity","volume":"15","author":"Mahmoud","year":"2020","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824001895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824001895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:50:39Z","timestamp":1758617439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824001895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":40,"alternative-id":["S0045206824001895"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107284","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel benzimidazole derivatives as potent HDACs inhibitors against leukemia with (Thio)Hydantoin as zinc-binding moiety: Design, synthesis, enzyme inhibition, and cellular mechanistic study","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107284"}}